Search

Your search keyword '"Sirachainan, Nongnuch"' showing total 625 results
Start Over Author "Sirachainan, Nongnuch"
625 results on '"Sirachainan, Nongnuch"'

152. A novel 33‐Gene targeted resequencing panel provides accurate, clinical‐grade diagnosis and improves patient management for rare inherited anaemias

Author

Roy, Noémi B. A., primary, Wilson, Edward A., additional, Henderson, Shirley, additional, Wray, Katherine, additional, Babbs, Christian, additional, Okoli, Steven, additional, Atoyebi, Wale, additional, Mixon, Avery, additional, Cahill, Mary R., additional, Carey, Peter, additional, Cullis, Jonathan, additional, Curtin, Julie, additional, Dreau, Helene, additional, Ferguson, David J. P., additional, Gibson, Brenda, additional, Hall, Georgina, additional, Mason, Joanne, additional, Morgan, Mary, additional, Proven, Melanie, additional, Qureshi, Amrana, additional, Sanchez Garcia, Joaquin, additional, Sirachainan, Nongnuch, additional, Teo, Juliana, additional, Tedgård, Ulf, additional, Higgs, Doug, additional, Roberts, David, additional, Roberts, Irene, additional, and Schuh, Anna, additional

Published
2016
Full Text
View/download PDF

156. LMI-01DEVELOPMENT OF CLINICAL GUIDELINES FOR THE TREATMENT OF LOW GRADE GLIOMAS IN LOWER AND LOWER MIDDLE INCOME COUNTRIES – A SIOP PODC INITIATIVE

Author

Hessissen, Laila, primary, Amayiri, Nisreen, additional, Mushtaq, Naureen, additional, Sirachainan, Nongnuch, additional, Anacak, Yavuz, additional, Mitra, Dipayan, additional, Figaji, Anthony, additional, Meeteren, Antoinette Schouten-van, additional, Sullivan, Michael, additional, Davidson, Alan, additional, Parkes, Jeannette, additional, Bouffet, Eric, additional, and Bailey, Simon, additional

Published
2016
Full Text
View/download PDF

157. HG-14OUTCOMES OF CHILDREN WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS TREATED WITH NIMOTUZUMAB®AND IRINOTECAN

Author

Sirachainan, Nongnuch, primary, Pakakasama, Samart, additional, Anurathapan, Usanarat, additional, Hansasuta, Ake, additional, Boonkerd, Attaporn, additional, Dhanachai, Mantana, additional, Larbcharoensub, Noppadol, additional, Klaisuban, Wipawi, additional, Sanpote, Watinee, additional, Lertthammakiat, Surapong, additional, Sripaiboonkij, Nintita, additional, Lusawat, Apasri, additional, Natesirinilkul, Rungrote, additional, and Hongeng, Suradej, additional

Published
2016
Full Text
View/download PDF

162. R147W in PROC Gene Is a Risk Factor of Thromboembolism in Thai Children.

Author

Sirachainan, Nongnuch, Chuansumrit, Ampaiwan, Sasanakul, Werasak, Yudhasompop, Najwa, Mahaklan, Lalita, Vaewpanich, Jarin, Charoenkwan, Pimlak, Kanjanapongkul, Somjai, Visudtibhan, Anannit, and Wongwerawattanakoon, Pakawan

Abstract

The p.R147W mutation, the c.C6152T in exon 7, causing a change in amino acid from arginine to tryptophan of the PROC gene has been reported as a common mutation in Taiwanese populations with venous thromboembolism (VTE). The present study aimed to identify the prevalence of p.R147W in the Thai population and children with TE and the risk of developing TE. Patients aged ⩽18 years diagnosed with TE were enrolled. The PROC gene was amplified by polymerase chain reaction using a specific primer in exon 7. The restriction fragment length polymorphism was designed using MwoI restriction enzyme. A total of 184 patients and 690 controls were enrolled. The most common diagnosis of TE was arterial ischemic stroke (AIS), at 100 (54.3%), followed by VTE, at 38 (20.6%), and cerebral venous sinus thrombosis (CVST), at 23 (12.5%). The prevalence of heterozygous and homozygous p.R147W in patients and controls was 9.5% versus 5.8% and 2.7% versus 0.1%, respectively. Heterozygous p.R147W had odds ratios (ORs) of 1.8 (95% confidence interval [CI]: 1.0-3.2, P = .04), 3.2 (95% CI: 1.2-8.2, P = .009), and 4.5 (95% CI: 1.6-12.8, P = .002) of developing overall TE, VTE, and CVST, respectively. Homozygous p.R147W had ORs of 20.2 (95% CI: 2.3-173.7, P < .001), 21.4 (95% CI: 2.2-207.9, P < .001), and 43.3 (95% CI: 3.8-490.6, P < .001) of developing overall TE, AIS, and CVST, respectively. This study suggested that p.R147W is a common mutation and increased risk of TE in Thai children. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

163. Incidences, risk factors and outcomes of neonatal thromboembolism.

Author

Sirachainan, Nongnuch, Limrungsikul, Anchalee, Chuansumrit, Ampaiwan, Nuntnarumit, Pracha, Thampratankul, Lunliya, Wangruangsathit, Somporn, Sasanakul, Werasak, and Kadegasem, Praguywan

Subjects
*THROMBOEMBOLISM, *NEWBORN infants, *THROMBOEMBOLISM in children, *PROTEIN C, *TERTIARY care
Abstract

Background: The incidences of thromboembolism (TE) in neonates were reported to be around 0.51 per 10,000 live births per year for overall TE and 24 per 10,000 NICU admissions per year. As the incidences of TE in children and adults are lower in Asian populations, the incidences, risk factors, and outcomes of neonatal TE may be different to those reports from other countries.Objectives: To determine the incidences, risk factors, and outcomes of neonatal TE in a tertiary care hospital in Thailand.Materials and Methods: A retrospective study between the years 1998 and 2015.Results: From a total of 2463 neonatal admissions, 28 patients were diagnosed with TE. The female/male ratio was 1:1.2. The breakdown of diagnoses of neonatal TE were arterial ischemic stroke (AIS; 36%), arterial TE (ATE; 29%), deep vein thrombosis (DVT; 14%), cerebral venous sinus thrombosis (CVST; 11%), renal vein thrombosis (RVT; 3%), and purpura fulminans (2%). Underlying diseases were identified 57.1% of patients. The most common thrombophilic risk factor was protein C (PC) deficiency (14.3%). The overall mortality rate was 14.3%.Conclusion: The most common TE was AIS. PC deficiency was the most prevalent inherited risk factor, especially in neonates without precipitating factors. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

168. PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP)

Author

Bussel, James B., primary, Grainger, John D., additional, Garcia de Miguel, Purificacion, additional, Despotovic, Jenny M., additional, Locatelli, Franco, additional, Chotsampancharoen, Thirachit, additional, Donyush, Elena K., additional, Sevilla Navarro, Julian, additional, Pongtanakul, Bunchoo, additional, Komvilaisak, Patcharee, additional, Sosothikul, Darintr, additional, Blanchette, Victor S., additional, Drelichman, Guillermo I., additional, Krishnamurti, Lakshmanan, additional, Sirachainan, Nongnuch, additional, Connor, Philip, additional, David, Michele, additional, Holzhauer, Susanne, additional, Lebedev, Vladimir, additional, Lemons, Richard S., additional, Pospisilova, Dagmar, additional, Ramenghi, Ugo, additional, Boayue, Koh B., additional, Matthews, Dana C., additional, Marcello, Lisa M., additional, Iyengar, Malini, additional, Chan, Geoffrey W., additional, Chagin, Karen D., additional, Theodore, Dickens, additional, Bakshi, Kalpana K., additional, and Bailey, Christine K., additional

Published
2014
Full Text
View/download PDF

174. Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors

Author

Chuansumrit,Ampaiwan, Angchaisuksiri,Pantep, Sirachainan,Nongnuch, Chuansumrit,Ampaiwan, Angchaisuksiri,Pantep, and Sirachainan,Nongnuch

Abstract

Ampaiwan Chuansumrit1, Pantep Angchaisuksiri2, Nongnuch Sirachainan11Departments of Pediatrics and 2Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University,  Bangkok, ThailandAbstract: Hemophilia patients with inhibitors faced the constraint of inadequate treatment for several years before the era of recombinant factor VIIa (rFVII). Initially, rFVIIa was used in the compassionate-use programs. After a worldwide license was issued, more than 1.5 million doses were administered. Bleeding of joints and muscles was controlled effectively by means of an early home treatment program, with either a standard dose of 90 μg/kg every 2 to 3 hours for a few doses or a single dose of 270 μg/kg. For more serious bleeding episodes or minor surgery, an initial dose of 90 μg/kg was given every 2 hours for 24 to 48 hours followed by increased intervals of 3 to 6 hours according to the severity of bleeding and efficacy of bleeding control. In cases of major surgery such as orthopedic procedures, the same regimen can be applied except for a higher initial dose of 120 to 180 μg/kg. However, increasing the dose should be considered if there are unexpected bleeding complications since the half-life and clearance of rFVIIa differ between individuals. In addition, prophylaxis is administered to a small number of patients. Finally, the reported thromboembolic events found in hemophilia patients with inhibitors receiving rFVIIa are extremely low, much less than 1%.Keywords: bleeding disorder, hemophilia, inhibitor, NovoSeven, recombinant factor VIIa

Published
2010

178. Curative Stem Cell Transplantation for Severe Hb H Disease Manifesting From Early Infancy: Phenotypic and Genotypic Analyses.

Author

Surapolchai, Pacharapan, Sirachainan, Nongnuch, So, Chi-Chiu, Hongeng, Suradej, Pakakasama, Samart, Anurathapan, Usanarat, and Chuansumrit, Ampaiwan

Subjects
*STEM cell transplantation, *STEM cell culture, *CELL transplantation, *CELLULAR therapy, *PROGENITOR cells, *INFANTS, *HEMOGLOBINS
Abstract

Most people with Hb H disease live normal lives; however, a minority of cases requires lifelong regular transfusions. An atypical form of nondeletional Hb H disease was reported in a Thai boy, characterized by severe persistent hemolytic anemia since the age of 2 months. Molecular diagnosis revealed the apparent compound heterozygosity for the Southeast Asian (− −SEA) and α2 polyadenylation (polyA) signal (AATAAA>AATA− −) deletions. The proband was successfully treated with allogeneic hematopoietic stem cell transplantation (HSCT). Accurate phenotypic and genotypic diagnosis in atypically severe Hb H disease is helpful for the understanding of its pathophysiology, the institution of appropriate management, and provision of genetic counseling and prenatal diagnosis. Hematopoietic stem cell transplantation is a potentially curative treatment option for this severe α-thalassemia (α-thal) syndrome. [ABSTRACT FROM PUBLISHER]

Published
2016
Full Text
View/download PDF

179. The Use of Hematocrit Level for Predicting the Efficiency of Peripheral Blood CD34+ Cell Collection After G-CSF Mobilization in Healthy Donors.

Author

Pornprasertsud, Nida, Niparuck, Pimjai, Kidkarn, Ruangtong, Puavilai, Teeraya, Sirachainan, Nongnuch, Pakakasama, Samart, Hongeng, Suradej, Jootar, Saengsuree, and Ungkanont, Artit

Abstract

Recently, peripheral blood siem cell (PBSC) has been widely used and replaced bone marrow (BM) as the stem cell source in allogeneic hematopoietic stem cell transplantation (HSCT) because of a more rapid engraftment, easier accessibility, and lower risk of donor complications. We, therefore, report the predicting factors for the high PBSC harvest yields in 50 healthy donors. Among the 50 donors, median collected CD34 + cell number was 4.6 × 106kg (1.5-16.3 × 106/kg). Number of circulating CD34+ cells and hematocrit (HCT) level increased parallelly whereas peripheral CD34+ cell numbers were decreased with increasing donor age. In univariate analysis, HCT level ⩾ 35.5% at the time of PBSC collection was significantly associated with high PBSC number (> 5.0 × 106 cells/kg) and donor aged <30 years was significantly associated with collected CD34+ cells>6.0 × 106/kg, P = 0.03. HCT level >35.5% was an independent parameter for high WBC count (>50 × 107L), P<0.05. None of donor who had both HCT < 35.5% and WBC < 50 × 109/L had circulating CD34+ cells⩾5.0 × 106/kg. Platelet count>200 × 109/L was found significantly in donors with WBC ⩾ 40 × 10y/L (P = 0.03) and HCT ⩾ 35.5%, P<0.05. Collected PBSC number tended to be higher in our donors with high levels of HCT, WBC, and platelet. We also found that HCT and platelet levels in our donors decreased after receiving G-CSF administration compared with the initial complete blood counts (CBC) results. We, therefore, concluded that HCT level at the time of initiation leukapheresis was an important predictor for PBSC collection yields. J. Clin. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

181. Establishment of Carrier Detection and Prenatal Diagnosis Service for Hemophilia in a Developing Country: Experience From International Hemophilia Training Center-Bangkok.

Author

Chuansumrit, Ampaiwan, primary, Sirachainan, Nongnuch, additional, Angchaisuksiri, Pantep, additional, Sasanakul, Werasak, additional, Wongwerawattanakoon, Pakawan, additional, Kadegasem, Praguywan, additional, Promsonthi, Patama, additional, and Lamthean, Hathaiwut, additional

Published
2012
Full Text
View/download PDF

188. Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy

Author

Sirachainan, Nongnuch, primary, Nuchprayoon, Issarang, additional, Thanarattanakorn, Pattra, additional, Pakakasama, Samart, additional, Lusawat, Apasri, additional, Visudibhan, Anannit, additional, Dhanachai, Mantana, additional, Larbcharoensub, Noppadol, additional, Amornfa, Jiraporn, additional, Shotelersuk, Kanchana, additional, Katanyuwong, Kamornwan, additional, Tangkaratt, Saipin, additional, and Hongeng, Suradej, additional

Published
2011
Full Text
View/download PDF

191. Impaired Glucose Tolerance and Insulin Resistance in Survivors of Childhood Acute Lymphoblastic Leukemia: Prevalence and Risk Factors

Author

Surapolchai, Pacharapan, primary, Hongeng, Suradej, additional, Mahachoklertwattana, Pat, additional, Pakakasama, Samart, additional, Winaichatsak, Angkana, additional, Wisanuyothin, Nittaya, additional, Pasomsub, Ekawat, additional, Mahasirimongkol, Surakameth, additional, and Sirachainan, Nongnuch, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results